Evidence map›Paper›PMID 33959814›Full record

ArticlePediatric nephrology (Berlin, Germany)2021

Factors associated with the absence of pharmacological treatment for common modifiable complications in children with chronic kidney disease.

Yunwen Xu, Derek K Ng, Susan L Furth, Bradley A Warady, Mark M Mitsnefes

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00327860 (Chronic Kidney Disease in Children Prospective Cohort Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00327860 recruitingnot on this map

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

TypeobservationalSponsorJohns Hopkins Bloomberg School of Public HealthRan2003 to 2028Enrolled1,300ConditionsChronic Kidney Disease
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Yunwen XuDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Derek K NgDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Susan L FurthDepartment of Pediatrics, Division of Nephrology, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Bradley A WaradyDepartment of Pediatrics, Division of Nephrology, Children's Mercy Kansas City, Kansas City, MO, USA.
Mark M MitsnefesDivision of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, MLC: 7022, 3333 Burnet Avenue, Cincinnati, OH, 45229-3039, USA. mark.mitsnefes@cchmc.org.ORCID 0000-0002-9904-0250
Johns Hopkins University · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USCincinnati Children's Hospital Medical Center · US

Funding

Chronic Kidney Disease in Children Study (C-Kid)U01DK066174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SUSAN L. FURTH · 2003 to 2026
$25.1M
CKiD Cardiovascular Testing Travel SupplementU01DK066143 · NIDDK · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Bradley Alan Warady · 2003 to 2026
$24.2M
The Kidney Disease in Children Data Management and Analysis Center (KIDMAC)U24DK066116 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Derek K Ng · 2018 to 2026
$12.6M
Central Biochemistry Laboratory of the CKID ConsortiumU24DK082194 · NIDDK · UNIVERSITY OF ROCHESTER · PI SCHWARTZ, GEORGE J · 2018 to 2022
$1.7M
NIDDK NIH HHS U01 DK066143NIDDK NIH HHS U01 DK066174NIDDK NIH HHS U24 DK066116NIDDK NIH HHS U24 DK082194
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is associated with many comorbidities requiring complex management. We described treatment patterns for common modifiable CKD complications (high blood pressure, anemia, hyperphosphatemia, and acidosis) according to severity of CKD and examined factors associated with the absence of drug therapy, among participants with a persistent comorbidity, for 1 year in children enrolled in the CKiD study.

methodsA total of 703 CKiD participants contributed 2849 person-visits over a median 3.5 years of follow-up. Using pairs of annual visits, we examined whether participants with abnormal biomarker levels at the first (index) visit persisted in the abnormal levels 1 year later according to CKD risk stage. Multivariate analyses identified demographic and clinical factors associated with the absence of drug therapy among those with persistent comorbid conditions for 1 year.

resultsThe overall proportions of person-visits prescribing therapy at 1-year follow-up for treating anemia, acidosis, hyperphosphatemia, and high blood pressure were 54%, 45%, 29%, and 81%, respectively. The frequency of therapy increased with advanced CKD risk stage for all comorbidities; however, 19-23% of participants with acidosis, 24-27% with anemia, and 30-39% with hyperphosphatemia at high-risk stages (E and F) were not prescribed appropriate therapy despite the persistence of abnormal levels of these biomarkers for at least 1 year. The resolution of comorbidities at advanced CKD stages without treatment was unlikely.

conclusionsMany children with CKD in the CKiD cohort did not receive pharmacological treatment for common and persistent modifiable comorbidities, even in severe CKD risk stages.

Indexed as

AnemiaHyperphosphatemiaHypertensionRenal Insufficiency, ChronicHumansProspective StudiesChildrenCKD stageTreatment initiation

Identifiers

PMID33959814
PMCPMC8981496
OpenAlexW3157856760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.